Bionime Corporation

Taiwan Stock Exchange 4737.TW

Bionime Corporation Price to Earnings Ratio (P/E) on January 14, 2025: 537.34

Bionime Corporation Price to Earnings Ratio (P/E) is 537.34 on January 14, 2025, a -22.97% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Bionime Corporation 52-week high Price to Earnings Ratio (P/E) is 709.07 on January 24, 2024, which is 31.96% above the current Price to Earnings Ratio (P/E).
Bionime Corporation 52-week low Price to Earnings Ratio (P/E) is 535.80 on January 13, 2025, which is -0.29% below the current Price to Earnings Ratio (P/E).
Bionime Corporation average Price to Earnings Ratio (P/E) for the last 52 weeks is 641.30.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Taiwan Stock Exchange: 4737.TW

Bionime Corporation

CEO	Mr. Chun-Mu Huang
IPO Date	Dec. 23, 2010
Location	Taiwan
Headquarters	No. 100, Daqing Street
Employees	1,111
Sector	Health Care
Industries Medical Instruments Biotechnology Pharmaceuticals

Description

Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Algeria, Egypt, and internationally. The company offers blood glucose monitors, as well as accessories, such as test strips and lancing devices medical equipment companies, pharmacies, and hospitals. It is also involved in the provision of biotechnology services; examining of pharmaceuticals; and selling of precision instruments. The company was incorporated in 2003 and is based in Taichung, Taiwan.

Key trends

Past 5 years